Long, Thorir Einarsson http://orcid.org/0000-0003-2377-7886
Indridason, Olafur Skuli
Palsson, Runolfur http://orcid.org/0000-0001-6763-1702
Rognvaldsson, Sæmundur http://orcid.org/0000-0003-2162-8414
Love, Thorvardur Jon
Thorsteinsdottir, Sigrun http://orcid.org/0000-0001-5017-3530
Sverrisdottir, Ingigerdur Solveig
Vidarsson, Brynjar
Onundarson, Pall Torfi
Agnarsson, Bjarni Agnar
Sigurdardottir, Margret
Thorsteinsdottir, Ingunn
Olafsson, Isleifur
Thordardottir, Asdis Rosa
Eythorsson, Elias
Jonsson, Asbjorn
Gislason, Gauti http://orcid.org/0000-0003-4710-0781
Olafsson, Andri
Steingrimsdottir, Hlif
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Durie, Brian G. M.
Harding, Stephen
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Kristinsson, Sigurdur Yngvi http://orcid.org/0000-0002-4964-7476
Article History
Received: 20 June 2022
Revised: 31 August 2022
Accepted: 1 September 2022
First Online: 14 September 2022
Competing interests
: Dr. Landgren has received grant support from: NCI/NIH, FDA, LLS, Rising Tide Foundation, Memorial Sloan Kettering Cancer Center, MMRF, IMF, Paula, and Rodger Riney Foundation, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; has received honoraria for scientific talks/participated in advisory boards for: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by: Takeda, Merck, Janssen, Theradex. Dr. Hultcrantz has recevied grant support from GSK, Amgen, Daiichi Sankyo, Cosette Pharmaceuticals, and has received honoraria for scientific talks/participated in advisory boards for BMS, Curio Science, and Intellisphere LLC. All other authors declare no potential conflicts of interest.